Literature DB >> 35611128

Positioning Medications: Yesterday, Today, and Tomorrow.

.   

Abstract

Entities:  

Year:  2021        PMID： 35611128      PMCID： PMC9122059     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Authors:  Bruce E Sands; Laurent Peyrin-Biroulet; Edward V Loftus; Silvio Danese; Jean-Frédéric Colombel; Murat Törüner; Laimas Jonaitis; Brihad Abhyankar; Jingjing Chen; Raquel Rogers; Richard A Lirio; Jeffrey D Bornstein; Stefan Schreiber
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

Review 2.  First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.

Authors:  Siddharth Singh; Mohammad Hassan Murad; Mathurin Fumery; Parambir S Dulai; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2020-01-13       Impact factor: 11.382

Review 3.  Positioning Therapies in the Management of Crohn's Disease.

Authors:  Nghia H Nguyen; Siddharth Singh; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2019-10-30       Impact factor: 11.382

4.  Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).

Authors:  Laurent Peyrin-Biroulet; Edward V Loftus; Jean-Frédéric Colombel; Silvio Danese; Raquel Rogers; Jeffrey D Bornstein; Jingjing Chen; Stefan Schreiber; Bruce E Sands; Richard A Lirio
Journal:  Gastroenterology       Date:  2021-06-16       Impact factor: 22.682
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.